By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sunesis Pharmaceuticals, Inc. 

395 Oyster Point Boulevard
Suite 400
South San Francisco  California  94080  U.S.A.
Phone: 650-266-3500 Fax: 650-266-3501


Sunesis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs. We have built our product candidate portfolio through internal discovery and the in-licensing of novel cancer therapeutics. We are advancing our product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. We believe the quality and breadth of our product candidate pipeline, platform technology, strategic collaborations and scientific team will enable us to become a fully integrated biopharmaceutical company with a diversified portfolio of novel therapeutics for major diseases.

We are advancing three proprietary oncology product candidates, SNS-595, SNS-032 and SNS-314, through in-house research and development efforts. All three are inhibitors of the cell division process, known as cell-cycle inhibitors, intended for the treatment of cancer. Our lead product candidate, SNS-595, is a novel cytotoxic. Sunesis is currently conducting three Phase 2 clinical trials with its lead product candidate, SNS-595 in non-small-cell lung cancer, small-cell lung cancer and ovarian cancer. A Phase 1 clinical trial in patients with advanced acute leukemias is underway; a second Phase 1 trial is being planned with SNS-595 in combination with Ara-C in patients with advanced acute leukemias. A second product being developed clinically is SNS-032, which is in one Phase 1/2 clinical study in patients with advanced solid tumors, and a second Phase 1 is being planned in patients with advanced B-lymphoid malignancies. Sunesis is also developing SNS-314, which is expected to enter Phase 1 clinical trials in early 2007. The company holds worldwide development and commercialization rights to SNS-595, SNS-032 (for diagnostic and therapeutic applications) and SNS-314, the Aurora kinase inhibitor program.

We have developed a proprietary method of discovering drugs in pieces, or fragments. We call this fragment-based discovery approach ''Tethering®''. Tethering® is a process whereby a target protein known to be involved in a disease process is engineered to facilitate the binding of small drug fragments. Once a small fragment is identified, the fragment is built out using the target protein's surface as a template to make a new full-size therapeutic compound. We combine Tethering® with other drug discovery tools, such as structure-based design and medicinal chemistry, to discover and develop novel therapeutics for major diseases. In addition to its use in our internal drug discovery efforts, Tethering® is the basis of our four strategic collaborations with Biogen Idec, Johnson & Johnson PRD and Merck. Since June 2004, each of our current collaboration partners has either extended its existing collaboration or entered into a new collaboration with our company. We believe that our strategic collaborations will enable us to leverage and expand our internal development capabilities, manage our cash expenditures and diversify risk across our pipeline.

Last Updated: 01-09-2007

Key Statistics

Ownership: Public

Web Site: Sunesis
Symbol: SNSS




Biogen (California)  Cancer Therapeutics

Millennium Pharmaceuticals, Inc. (South San Francisco, California)  Cancer Therapeutics

Sumitomo Dainippon Pharma  Cancer Therapeutics

Company News
Sunesis (SNSS) Reports Second Quarter 2017 Financial Results And Recent Highlights 7/27/2017 11:28:57 AM
Sunesis (SNSS) To Host Conference Call On July 27th To Discuss Second Quarter 2017 Financial Results And Recent Highlights 7/24/2017 11:30:03 AM
Sunesis (SNSS) Announces First Patient Dosed In Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-Inhibitor SNS-062 In Adults With Chronic Lymphocytic Leukemia And Other B-Cell Malignancies 7/19/2017 11:14:50 AM
Sunesis (SNSS) Added To Russell Microcap Index 6/26/2017 12:17:17 PM
Sunesis (SNSS) Announces Presentation Of Updated Results From Washington University-Sponsored Phase I/Cohort Expansion Trial Of Vosaroxin Plus Azacitidine In Patients With MDS At The European Hematology Association Annual Meeting 6/23/2017 8:38:08 AM
Sunesis (SNSS) Reports First Quarter 2017 Financial Results And Recent Highlights 5/8/2017 10:06:40 AM
Bay Area's Sunesis (SNSS) Drops After Withdrawing Leukemia Drug Application 5/2/2017 6:15:03 AM
Sunesis (SNSS) Announces Presentation Of The Ohio State University-Sponsored Preclinical Study Of BTK Inhibitor SNS-062 At AACR Annual Meeting 4/3/2017 1:42:44 PM
Sunesis (SNSS) Announces Submission Of Responses To The EMA Day 180 List Of Outstanding Issues For Marketing Authorization Application For Vosaroxin 3/22/2017 10:30:59 AM
Sunesis (SNSS) Reports Fourth Quarter And Full-Year 2016 Financial Results And Recent Highlights 3/9/2017 10:30:52 AM